(603079)"Zhejiang Shengda Bio-Pharm Co., Ltd."Report for Q3 2026
Filed with SSE · Stock code 603079 · · 11 pages · Chinese
Summary by 6ix AI
The report indicates a decline in revenue and net profit compared to the same period last year, with significant decreases in earnings per share. The company also highlights that the financial statements have not been audited for this quarter.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Zhejiang Shengda Bio-Pharm Co., Ltd. on 6ix
Earlier from Zhejiang Shengda Bio-Pharm
- (603079)"Zhejiang Shengda Bio-Pharm Co., Ltd."Announcement on Progress in Repurchasing Shares
- (603079)"Zhejiang Shengda Bio-Pharm Co., Ltd."Announcement on Progress in Using Idle Raised Funds for Cash Management
- (603079)"Zhejiang Shengda Bio-Pharm Co., Ltd."Announcement on Redemption upon Maturity of Cash Management Products Purchased with Idle Raised Funds
- Announcement on Progress in Opening Dedicated Settlement Account for Cash Management Products Purchased with Raised Funds and Using Idle Raised Funds for Cash Management
Follow Zhejiang Shengda Bio-Pharm into a list and get an email when it puts out news.
Follow Zhejiang Shengda Bio-Pharm